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Abstract Low-turnover bone disease is a complication of
chronic kidney disease and a long-term steroid therapy.
Currently, the only bone anabolic treatment available is
teriparatide (TPTD). So far, no data exist in heart transplant
patients, and only one single case with histomorphometric anal-
ysis of a dialysis patient with a low-turnover bone disease has
been published. The current report shows the effect of a 1-year
TPTD therapy in a cardiac transplant patient with 10 vertebral
and 3 peripheral fractures who had developed a chronic kidney
failure while receiving triple immunosuppressive therapy. A
transiliac bone biopsy following tetracycline labeling was per-
formed prior and after 1 year of treatment, showing an increase
in the bone formation and improvement of the structural indices
(20-fold increase of osteoid volume/bone volume, fourfold in-
crease of osteoid surface/bone surface and increases of wall
thickness (+15%), trabecular thickness (+9%), and trabecular
number (+38%)). Bone mineral density was stable, no new
vertebral fractures had occurred, the therapy was well-tolerated,
and the patient improved clinically.
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Introduction
Transplantation bone disease and chronic kidney disease-
mineral bone disorders (CKD-MBD) are two entities indepen-
dently associated with a high fracture risk [1, 2].
Steroid treatment combined with increasing serum
sclerostin levels due to a kidney damage may induce
an adynamic bone disease [3–6]. Decreasing kidney
function is a common late complication of immunosup-
pressive therapy and may lead to CKD-MBD [2]. The
decrease of bone mass is aggravated by a deterioration
of bone microarchitecture not only in transplantation
bone disease but also in CKD [7–11]. At the time of
initiation of dialysis, 50% of the patients have prevalent
fractures [10–12], and approximately half of the patients
on chronic dialysis have a low-turnover bone disease
[13]. Whereas there are promising data for denosumab
treatment in patients with chronic kidney disease [12],
prospective data for teriparatide (TPTD) in CKD pa-
tients are scarce [14, 15]. Only recently, one report of
TPTD treatment leading to an improvement of bone
remodeling in a dialysis patient was published [16].
We report on the treatment effects of TPTD on the
histomorphometric indices, bone mineral density, fractures,
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Case
A 58-year-old white man who had received a cardiac trans-
plant due to myocarditis 7 years earlier was followed up at the
Medical University Graz, a tertiary center in the southern part
of Austria, Europe. The first osteoporosis assessment of the
patient was carried out 2 months following surgery.
According to the WHO classification, osteopenia was diag-
nosed by measuring the bone mineral density (BMD)—using
the dual X-ray technology (GE Lunar iDXA, GE Healthcare,
UK)—at the spine (0.688 g/cm2, T-score −2.4), the neck re-
gion of the hip (0.698 g/cm2, T-score −1.9), and the total
region of the hip (0.762 g/cm2, T-score −1.8). A standardized
spinal X-ray revealed one moderate vertebral fracture accord-
ing to the Genant classification [17]. The patient had no his-
tory of peripheral fractures or previously diagnosed osteopo-
rosis. He received a triple immunosuppressive therapy
consisting of 5 mg aprednisolone, cyclosporine A and myco-
phenolate mofetil, had normal laboratory results including
normal kidney function, and was started on bisphosphonate
therapy with quarterly intravenous ibandronate 2 mg on top
of the daily 500 mg calcium and 1200 IU cholecalciferol
(Vitamin D) [8]. After 2 years, the patient was lost to follow
up but returned 5 years later due to an acute back pain. He
was still on the same triple immunosuppressive therapy and
had developed impaired kidney function (GFR 21 ml/min/
1.73m2). Other lab results showed a normal serum calcium
and phosphate, elevated serum levels of iPTH, crosslaps
(sCTX), osteocalcin (OC), procollagen type I N propeptide
(PINP) [18]—due to accumulation with decreased renal func-
tion [18–21]—and normal levels of 25 (OH) vitamin D
(VitD), 5 tartrate-resistant acid phosphatase (TRAP5b), and
bone alkaline phosphatase (bALP) (see Table 1). He had
stopped bisphosphonate therapy 4 years ago and was current-
ly receiving 500 mg calcium carbonate as a phosphate binder
twice daily, as well as 2000 IU vitamin D. During the past
2 years, he had sustained a wrist fracture, a rib fracture, and
an ankle fracture. A standardized X-ray of the spine revealed
10 vertebral fractures—4 severe, 1 moderate, and 5 mild—
according to [17]. BMD measurement was invalid at the
spine due to vertebral fractures and aortic calcification
(Agatston score 804). BMD at the hip region was severely
reduced [neck 0.453 g/cm2 T-score −3.9) and total hip
0.526 g/cm2 (T-score −3.4] reflecting a loss of 35 and 34%
compared to the BMD results obtained 7 years earlier on the
same DXA device. Iliac crest biopsy following tetracycline
double labeling was performed. Histomorphometric analysis
(OSTEOMEASURE) revealed an adynamic bone disease and
destroyed bone microarchitecture (see Fig. 1 and Table 2)
[22] with reduced osteoid and eroded surface and an absence
of double labels—only two single labels could be defined.
The patient was trained on self-injections with TPTD.
Serum calcium and phosphate levels stayed within a normal
range and were monitored daily, later at least every other
week. Serum PTH and vitamin D levels did not change, bone
markers increased, and kidney function remained stable
(Table 1). The patient improved clinically with an increase of
the HRQoL (EQ-5D) and a decrease of the EQ-VAS score
(Table 1). After 1 year, a second bone biopsy showed
Table 1 Laboratory results at the baseline and after 1 year of therapy as
well as the changes in back pain and health-related quality of life
Laboratory parameters Baseline 1 year
S-Creatinine (0.6–1.3 mg/dl) 4.4 4.8
GFR (>70 ml/min/1.73m2) 21 19
S-Phosphate (0.87–1.45 mmol/l) 1.35 1.24
S-Calcium (2.2–2.65 mmol/l) 1.91 2.39
bALP (14–43 U/L) 34 45
TRAP5b (0.61–3.45 U/l) 3.32 3.87
sCTX (0.03–0.44 ng/ml) 1.55 1.87
Osteocalcin (1–35 ng/ml) 87 123
PINP (20–75 ng/ml) 184 546
iPTH (15–65 pg/ml) 112 98
25(OH)VitD (30-65 ng/ml) 31 34
EQ-5D [5–15] 11 7
EQ-VAS (0–100) 85 40
Fig. 1 On the left hand, a hematoxylin and eosin staining of the bone
biopsy prior to TPTD shows a lack of osteoid surfaces, eroded surfaces,
no osteoblasts or osteoclasts reflecting a low bone turnover. The
unstained cut at the baseline had no double labels. The unstained cut on
the right shows double tetracyline labels under teriparatide therapy—the
biopsy was taken after 1 year of TPTD treatment
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improvements of static and dynamic parameters (Table 2)
(Fig. 1). After TPTD was initiated, no new peripheral fracture
occurred, BMD remained stable, and spinal X-ray revealed no
new fracture but worsening of onemild to amoderate vertebral
fracture. No adverse events or rejection episodes occurred.
In total, the patient has received TPTD for 24 months, and
he is currently under denosumab 60 mg twice a year.
Discussion
To our knowledge, this is the first case report on TPTD treatment
in transplantation bone disease describing a beneficial effect on
bone remodeling. This case grows intricate due to the adynamic
bone disease as a likely consequence of a long-term steroid treat-
ment, aggravated by chronic kidney disease. In the recently pub-
lished report of a dialysis patient without concomitant immuno-
suppressive therapy, positive effects on bone remodeling have
been published [16]. That 41-year-old dialysis patient showed a
marked improvement of histomorphometric parameters after
2 years of TPTD, together with a marked increase in BMD.
Similar to this case, our patient responded to TPTD with a near
fourfold increase of OS/BS, a 20-fold increase of OV, and a
normalization of ObS/BS. Even as soon as after 12 months, the
cancellous structural parameter improved (see Table 2). These
changes are in line with the data published earlier [22, 25], and
only changes in W. Th and BV were smaller—possibly due to
the shorter treatment duration. Compared to [16], in the case
described here, a marked anabolic effect was seen, with a man-
ifold increase of the bone formation indices. There is strong
evidence that the early period of TPTD treatment is dominated
by a bone formation [26, 27]. Our patient had his second biopsy
after 1 year. Likely, a chronic steroid therapy and a low-turnover
CKD-MBD accounted for a delayed response to TPTD, and the
excessive response of bone formation in this patient reflects the
early predominately anabolic effect [27]. In CKD patients with a
low-turnover bone disease, TPTD seems to increase BMD [15,
28], but the data on histomorphometric response are limited to
one case [16]. With denosumab, a treatment option for patients
with normal- to high-turnover CMD, MBD has become avail-
able [12], but again histomorphometric data in CKD patients are
lacking.
The opportunity to treat a high-turnover bone disease in a
kidney failure with denosumab and a low-turnover
CKD-MBD with TPTD on the one hand and the lack of any
prospective interventional studies, so far, must encourage
clinicians to start treating patients according to their
underlying pathophysiology which can be assessed using
histomorphometric diagnosis of bone turnover status. It must
be acknowledged, however, that not a single prospective in-
terventional study exists so far.
Our case demonstrates that even in a CKD-MBD patient
with a triple immunosuppressive therapy including a lifelong
treatment with steroids, adynamic bone disease responds to
teriparatide treatment and leads to a normalization of the dy-
namic parameters and improvement of the structural indices.
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Table 2 Histomorphometric
parameters prior and after
12 months of teriparatide
therapy—parameter and
abbreviation according to (23).





Bone volume/tissue volume (BV/TV) 14–30% 6.7 8.0 (+19)
Osteoid surface/bone surface (OS/BS) 7–25% 4.8 17.7 (+269)
Osteoid volume/bone volume (OV/BV) 0.3–3.1% 0.07 1.4 (+1900)
Osteoblast surface/bone surface (ObS/BS) 0–9.5% 0 4.5 (NA)
Eroded surface/bone surface (ES/BS) 1.75–7.0% 0.2 1.85 (+825)
Osteoclast surface/bone surface (OCS/BS) 0.0–2.0% 0.1 0.4 (+300)
Wall thickness (W. Th) 25.0–38.0 μm 17.6 20.3 (+15)
Trabecular number (TbN) 1.2–2.0/mm 0.89 1.23 (+38)
Trabecular thickness (TbTh) 127–165 μm 116.4 126.9 (+9)
Trabecular separation (Tb/Sp) 480–850 μm 987 865 (−12)
Mineralizing surface single label/bone surface
(MS/BS) 1.4–18%
2.1 17.9 (+752)
Mineral apposition rate (MAR) 0.36–0.63 μm/d 0 0.39 (NA)
Osteoporos Int (2017) 28:1149–1152 1151
1152 Osteoporos Int (2017) 28:1149–1152
References
1. Cohen A, Sambrook P, Shane E (2004) Management of bone loss
after organ transplantation. J Bone Miner Res 9:1919–1932
2. Ketteler M, Elder GJ, Evenepoel P, Ix JH, Jamal SA, Lafage-Proust
MH et al (2015) Revisiting KDIGO clinical practice guideline on
chronic kidney disease—mineral and bone disorder: a commentary
from a Kidney Disease: improving global outcomes controversies
conference. Kidney Int 87:502–528
3. Pelletier S1, Confavreux CB, Haesebaert J, Guebre-Egziabher F,
Bacchetta J, Carlier MC et al (2015) Serum sclerostin: the missing
link in the bone-vessel cross-talk in hemodialysis patients?
Osteoporos Int 26(8):2165–2174
4. Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D (2013
May) The relation between renal function and serum sclerostin in
adult patients with CKD. Clin J Am Soc Nephrol 8(5):819–823
5. de Oliveira RA, Barreto FC, Mendes M, dos Reis LM, Castro JH,
Britto ZM et al (2015 May) Peritoneal dialysis per se is a risk factor
for sclerostin-associated adynamic bone disease. Kidney Int 87(5):
1039–1045
6. Moysés RM, Schiavi SC (2015 Nov-Dec) Sclerostin, osteocytes,
and chronic kidney disease—mineral bone disorder. Semin Dial
28(6):578–586
7. Miller PD (2014 Aug) Bone disease in CKD: a focus on osteopo-
rosis diagnosis and management. Am J Kidney Dis 64(2):290–304
8. Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR,
Obermayer-Pietsch BM, Pilz S, Dimai HP et al (2009)
Ibandronate prevents bone loss and reduces vertebral fracture risk
in male cardiac transplant patients: a randomized double-blind,
placebo-controlled trial. J Bone Miner Res 24:1335–1344
9. Malluche HH, Porter DS, Monier-Faugere MC, Mawad H,
Pienkowski D (2012) Differences in bone quality in low- and
high-turnover renal osteodystrophy. J AmSocNephrol 23:525–532
10. Jamal SA, Gilbert J, Gordon C, Bauer DC (2006) Cortical pQCT
measures are associated with fractures in dialysis patients. J Bone
Miner Res 21:543–548
11. Nickolas TL1, Leonard MB, Shane E (2008) Chronic kidney dis-
ease and bone fracture: a growing concern. Kidney Int 74:721–731
12. Jamal SA1, Ljunggren O, Stehman-Breen C, Cummings SR, MR
MC, Goemaere S (2011) Effects of denosumab on fracture and
bone mineral density by level of kidney function. J Bone Miner
Res 26:1829–1835
13. Malluche HH, Mawad HW, Monier-Faugere MC (2011) Renal
osteodystrophy in the first decade of the new millennium: analysis
of 630 bone biopsies in black and white patients. J BoneMiner Res
26:1368–1376
14. Cejka D, Kodras K, Bader T, Haas M (2010) Treatment of
hemodialysis-associated adynamic bone disease with teriparatide
(PTH1-34): a pilot study. Kidney Blood Press Res 33:221–226
15. Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH (2007)
Teriparatide in postmenopausal women with osteoporosis and mild
or moderate renal impairment. Osteoporos Int 18(1):59–68
16. Palcu P, Dion N, Ste-Marie LG, Goltzman D, Radziunas I, Miller
PD et al (2015) Teriparatide and bone turnover and formation in a
hemodialysis patient with low-turnover bone disease: a case report.
Am J Kidney Dis 65:933–936
17. Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D,
et al. Comparison of semiquantitative visual and quantitative mor-
phometric assessment of prevalent and incident vertebral fractures
in osteoporosis. The study of osteoporotic fractures research group J
Bone Miner Res 1996;11(7):984–996.
18. Krege JH, Lane NE, Harris JM, Miller PD (2014) PINP as a bio-
logical response marker during teriparatide treatment for osteopo-
rosis. Osteoporos Int 25(9):2159–2171
19. Delanaye P, Souberbielle JC, Lafage-Proust MH, Jean G, Cavalier
E (2014) Can we use circulating biomarkers to monitor bone turn-
over in CKD haemodialysis patients? Nephrol Dial Transplant 29:
997–1004
20. Cavalier E, Bergmann P, Bruyère O, Delanaye P, Durnez A,
Devogelaer JP et al (2016) The role of biochemical of bone turn-
over markers in osteoporosis and metabolic bone disease: a consen-
sus paper of the Belgian Bone Club. Osteoporos Int 27:2181–2195
21. Fahrleitner-Pammer A, Herberth J, Browning SR, Obermayer-
Pietsch B, Wirnsberger G, Holzer H et al (2008) Bone markers
predict cardiovascular events in chronic kidney disease. J Bone
Miner Res 23(11):1850–1858
22. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF
(2003) Recombinant human parathyroid hormone (1-34)
[teriparatide] improves both cortical and cancellous bone structure.
J Bone Miner Res 18:1932–1941
23. Dempster DW, Compston JE, DreznerMK, Glorieux FH,Kanis JA,
Malluche H et al (2013) Standardized nomenclature, symbols, and
units for bone histomorphometry: a 2012 update of the report of the
ASBMR Histomorphometry Nomenclature Committee. J Bone
Miner Res 28:2–17
24. Recker RR, Kimmel DB, Parfitt AM, Davies KM, Keshawarz N,
Hinders S (1988) Static and tetracycline-based bone
histomorphometric data from 34 normal postmenopausal females.
J Bone Miner Res 3:133–144
25. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert
L et al (2001) Effects of daily treatment with parathyroid hormone
on bone microarchitecture and turnover in patients with osteoporo-
sis: a paired biopsy study. J Bone Miner Res 16(10):1846–1853
26. Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie LG,
Gallagher JC (2005) Early changes in biochemical markers of bone
formation correlate with improvements in bone structure during
teriparatide therapy. J Clin Endocrinol Metab 90:3970–3977
27. Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman
AB (2005) Effects of a one-month treatment with PTH(1-34) on
bone formation on cancellous, endocortical, and periosteal surfaces
of the human ilium. J Clin Endocrinol Metab 90:3970–3977
28. Mitsopoulos E, Ginikopoulou E, Economidou D, Zanos S,
Pateinakis P, Minasidis E (2012) Impact of long-term cinacalcet,
ibandronate or teriparatide therapy on bone mineral density of he-
modialysis patients: a pilot study. Am J Nephrol 36:238–244
